Certara, Inc. (NASDAQ:CERT) Receives $15.92 Consensus Price Target from Analysts

Certara, Inc. (NASDAQ:CERT - Get Free Report) has earned an average recommendation of "Hold" from the eight research firms that are currently covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $15.92.

A number of research analysts have recently issued reports on CERT shares. Barclays dropped their target price on Certara from $14.00 to $12.00 and set an "equal weight" rating on the stock in a report on Thursday, November 7th. Robert W. Baird dropped their target price on shares of Certara from $18.00 to $13.00 and set a "neutral" rating for the company in a report on Tuesday, November 5th. Finally, UBS Group raised Certara from a "neutral" rating to a "buy" rating and set a $16.00 price target on the stock in a research note on Friday, September 27th.

Insider Buying and Selling

In other Certara news, insider Patrick F. Smith sold 5,409 shares of the firm's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the sale, the insider now directly owns 50,091 shares of the company's stock, valued at $552,503.73. This trade represents a 9.75 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.39% of the company's stock.

Hedge Funds Weigh In On Certara

Several institutional investors and hedge funds have recently modified their holdings of CERT. Brown Brothers Harriman & Co. purchased a new position in shares of Certara during the 3rd quarter worth $27,292,000. Sei Investments Co. increased its stake in Certara by 39.5% in the second quarter. Sei Investments Co. now owns 997,871 shares of the company's stock valued at $13,821,000 after purchasing an additional 282,357 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in Certara by 40.7% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company's stock worth $45,691,000 after buying an additional 1,128,006 shares during the period. Daventry Group LP boosted its stake in Certara by 153.0% in the 2nd quarter. Daventry Group LP now owns 1,308,572 shares of the company's stock worth $18,124,000 after buying an additional 791,405 shares during the last quarter. Finally, Kayne Anderson Rudnick Investment Management LLC grew its holdings in Certara by 8.4% in the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 810,206 shares of the company's stock valued at $11,221,000 after buying an additional 62,912 shares during the period. Hedge funds and other institutional investors own 73.96% of the company's stock.

Certara Stock Up 1.0 %

CERT traded up $0.11 on Tuesday, reaching $10.65. The company's stock had a trading volume of 1,223,939 shares, compared to its average volume of 850,682. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara has a fifty-two week low of $9.41 and a fifty-two week high of $19.87. The stock has a 50 day moving average of $10.73 and a two-hundred day moving average of $12.14. The company has a market capitalization of $1.71 billion, a price-to-earnings ratio of -53.25, a P/E/G ratio of 5.86 and a beta of 1.53.

Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.11 by $0.02. The firm had revenue of $94.80 million for the quarter, compared to analyst estimates of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. Certara's revenue for the quarter was up 10.7% compared to the same quarter last year. During the same period last year, the business earned $0.06 EPS. As a group, analysts forecast that Certara will post 0.28 EPS for the current fiscal year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.